Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis-2027

PEPTIDE-BASED GASTROINTESTINAL DISORDERS THERAPEUTICS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

REPORT DESCRIPTION Peptide-Based Gastrointestinal Disorders Therapeutics Market - Overview Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis North America Peptide-Based Gastrointestinal Disorders Therapeutics Market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market. Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japanbased pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel syndrome. Browse Research Reports: https://www.coherentmarketinsights.com/ongoinginsight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate cyclase C receptors in the intestine and is used for the treatment of chronic constipation and irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal tract. Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics market growth over the forecast period. For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2028 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan. In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near future. Furthermore, increasing prevalence of gastrointestinal disorders is expected to rise the demand for peptide-based drugs, which will in turn drive the global peptide-based gastrointestinal disorders therapeutics market growth. For instance, according to the data published by the International Foundation for Functional Gastrointestinal Disorder in 2016, irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder and globally, around 10-15% of the population suffers from IBS.

ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

Turn static files into dynamic content formats.

Create a flipbook